GILD - NASDAQ
Gilead Sciences, Inc.
$128.99
-1.6%Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
At a Glance
Live SnapshotGilead Sciences, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Outstanding operational efficiency. The company generates substantial profit from core operations.
Net Profit Margin
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
Gilead Sciences, Inc. Income Statement
GILD • NASDAQ
| Gilead Sciences, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
29.4B | 28.8B | 27.1B | 27.3B | 27.3B | 24.7B | 22.4B | 22.1B | 26.1B | 30.4B | 32.6B | 24.9B | 11.2B | 9.7B | 8.4B | 7.9B | 7B | 5.3B | 4.2B | 3B | |
GROSS PROFIT | ||||||||||||||||||||
(3.9B) | (6.3B) | (6.5B) | (5.7B) | (6.6B) | (4.6B) | (4.7B) | (4.9B) | (4.4B) | (4.3B) | (4B) | (3.8B) | (2.9B) | (2.5B) | (2.1B) | (1.9B) | (1.6B) | (1.1B) | (768.8M) | (433.3M) | |
25.5B | 22.5B | 20.6B | 21.6B | 20.7B | 20.1B | 17.8B | 17.3B | 21.7B | 26.1B | 28.6B | 21.1B | 8.3B | 7.2B | 6.3B | 6.1B | 5.4B | 4.2B | 3.5B | 2.6B | |
OPERATING INCOME | ||||||||||||||||||||
(13.7B) | (20.8B) | (13B) | (14.3B) | (10.8B) | (16B) | (8.4B) | (8B) | (7.6B) | (8.5B) | (6.4B) | (5.8B) | (3.8B) | (3.2B) | (2.5B) | (2.1B) | (1.9B) | (1.5B) | (1.3B) | (957.5M) | |
(5.7B) | (6.1B) | (6.1B) | (5.7B) | (5.2B) | (5.1B) | (4.4B) | (4.1B) | (3.9B) | (3.4B) | (3.4B) | (3B) | (1.7B) | (1.5B) | (1.2B) | (1B) | (946.7M) | (797.3M) | (705.7M) | (573.7M) | |
(5.7B) | (5.9B) | (5.7B) | (5B) | (4.6B) | (5B) | (4.1B) | (3.9B) | (3.7B) | (5.1B) | (3B) | (2.9B) | (2.1B) | (1.8B) | (1.2B) | (1.1B) | (939.9M) | (721.8M) | (591M) | (383.9M) | |
11.8B | 1.7B | 7.6B | 7.3B | 9.9B | 4.1B | 4.3B | 8.2B | 14.1B | 17.6B | 22.2B | 15.3B | 4.5B | 4B | 3.8B | 4B | 3.5B | 2.7B | 2.2B | -758.8M | |
PRE-TAX INCOME | ||||||||||||||||||||
(1B) | (977M) | (944M) | (935M) | (1B) | (984M) | (995M) | (1.1B) | (1.1B) | (964M) | (688M) | (412M) | (307M) | (361M) | (205.4M) | (109M) | (69.7M) | (65.2M) | (0.0) | (0.0) | |
-1B | -696M | -568M | -829M | -1B | -984M | -995M | -1.1B | -1.1B | -964M | -688M | -412M | -307M | -361M | -205.4M | -109M | -27.3M | -5.8M | 0.0 | 0.0 | |
(2.3B) | (8.8B) | (1.2B) | (3.6B) | (939M) | (5.9B) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-2B | -972M | -746M | -1.5B | -1.6B | -2.4B | 873M | -401M | -595M | -536M | -534M | -409M | -316M | -398M | -138.8M | -48.7M | -27.3M | -5.8M | 105.8M | 120.5M | |
9.8B | 690M | 6.9B | 5.8B | 8.3B | 1.7B | 5.2B | 7.8B | 13.5B | 17.1B | 21.7B | 14.9B | 4.2B | 3.6B | 3.7B | 3.9B | 3.5B | 2.7B | 2.3B | -638.2M | |
NET INCOME | ||||||||||||||||||||
(1.3B) | (211M) | (1.2B) | (1.2B) | (2.1B) | (1.6B) | -204M | (2.3B) | (8.9B) | (3.6B) | (3.6B) | (2.8B) | (1.2B) | (1B) | (861.9M) | (1B) | (876.4M) | (702.4M) | (655M) | (551.8M) | |
8.5B | 480M | 5.7B | 4.6B | 6.2B | 123M | 5.4B | 5.5B | 4.6B | 13.5B | 18.1B | 12.1B | 3.1B | 2.6B | 2.8B | 2.9B | 2.6B | 2B | 1.6B | -1.2B |
SEC Filings
GILD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 20, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 20, 2026 | April 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 22, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 10, 2026 | February 10, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 19, 2025 | November 15, 2025 | 2025 |
Related Guides
Continue your GILD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.